Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia
1
Department of Hematology, Zigong First People’s Hospital, Zigong, China
|
3
Department of Hematology, The 923Rd Hospital of the Joint Logistics Support Force of the People’s Liberation Army, Nanning, China
|
Publication type: Journal Article
Publication date: 2025-03-18
scimago Q2
wos Q2
SJR: 0.862
CiteScore: 4.0
Impact factor: 2.4
ISSN: 09395555, 14320584
Abstract
Nucleoporin 98 (NUP98) fusion oncoproteins are associated with various hematologic malignancies. Acute myeloid leukemia (AML) with NUP98-NSD1 typically co-occurs with FLT3-ITD mutations, exhibiting poor initial responses to traditional chemotherapy. This case report describes a relapsed and refractory AML case co-expressing NUP98/NSD1 and FLT3/ITD after matched sibling haplo-identical allogeneic hematopoietic stem cell transplantation, achieving molecular remission with a salvage therapy combining selinexor, venetoclax, and azacitidine. To our knowledge, this is the first report demonstrating the effectiveness of this combination therapy for relapsed/refractory NUP98-NSD1+/FLT3-ITD + AML. This report highlights the potential synergy between selinexor and established AML therapies, suggesting a promising approach to improve outcomes for refractory AML patients.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
1
Total citations:
1
Citations from 0:
0
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Yang K. et al. Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia // Annals of Hematology. 2025. Vol. 104. No. 4. pp. 2545-2549.
GOST all authors (up to 50)
Copy
Yang K., Yang B., Zhou Y., Huang Q., Yin X. Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia // Annals of Hematology. 2025. Vol. 104. No. 4. pp. 2545-2549.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1007/s00277-025-06312-2
UR - https://link.springer.com/10.1007/s00277-025-06312-2
TI - Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia
T2 - Annals of Hematology
AU - Yang, Kun
AU - Yang, Beibei
AU - Zhou, Yali
AU - Huang, Qiuying
AU - Yin, Xiaolin
PY - 2025
DA - 2025/03/18
PB - Springer Nature
SP - 2545-2549
IS - 4
VL - 104
SN - 0939-5555
SN - 1432-0584
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2025_Yang,
author = {Kun Yang and Beibei Yang and Yali Zhou and Qiuying Huang and Xiaolin Yin},
title = {Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2025},
volume = {104},
publisher = {Springer Nature},
month = {mar},
url = {https://link.springer.com/10.1007/s00277-025-06312-2},
number = {4},
pages = {2545--2549},
doi = {10.1007/s00277-025-06312-2}
}
Cite this
MLA
Copy
Yang, Kun, et al. “Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia.” Annals of Hematology, vol. 104, no. 4, Mar. 2025, pp. 2545-2549. https://link.springer.com/10.1007/s00277-025-06312-2.